Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients.

International Journal of Hematology
Aamer AleemAbdulkarim Al-Momen

Abstract

Management of patients with immune thrombocytopenia (ITP) refractory to standard treatment is difficult. Recent studies show that rituximab, a chimeric anti-CD20 monoclonal antibody, is useful in the treatment of ITP. We retrospectively studied 24 patients who received 29 rituximab treatments for relapsed or refractory ITP. Patients had received a median of 3 treatment regimens before (range 1-8) and 11 patients had prior splenectomy. Responses were achieved in 19 of 29 (66%) treatments. The median time to response was 3 weeks (range 1-20) from the start of therapy and median duration of response was 13 weeks (range 1 week-55 months). Responses were mostly short lived and after a median follow-up of 22 months (range 2-70), 10 (34%) responses were sustained after 6 months, 7 (24%) responses sustained after 1 year and only 5 patients continued to have a response at last visit after 8, 10, 24, 30 and 54 months of follow-up. Previous splenectomy was associated with a poor response (p=0.034). Patients who failed rituximab and had prior multiple treatments including splenectomy, had a poor outcome of further therapies. We conclude that rituximab is well tolerated and is useful in some patients with relapsed or refractory ITP; however...Continue Reading

References

Nov 1, 1980·The American Journal of Medicine·V J PicozziW P Creger
May 1, 1995·The American Journal of Medicine·R StasiS Amadori
Feb 15, 1997·Annals of Internal Medicine·R McMillan
Mar 29, 2002·The New England Journal of Medicine·Douglas B Cines, Victor S Blanchette
Jul 23, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Nicola Di GaetanoJosée Golay
Jan 24, 2004·Leukemia & Lymphoma·Francesco ZajaRenato Fanin
Feb 14, 2004·European Journal of Haematology·Tadeusz Robak
Jun 18, 2004·The New England Journal of Medicine·Jonathan C W EdwardsTim Shaw
Mar 30, 2005·American Journal of Hematology·Peter BraendstrupHans C Hasselbalch
Jun 9, 2005·Blood·Douglas B Cines, James B Bussel
Aug 2, 2005·Cancer Treatment Reviews·Eva Kimby
Mar 22, 2006·Annals of Hematology·Francisco Javier PeñalverUNKNOWN Multi-institutional Retrospective Spanish Study Group on the Use of Rituximab in Refractory ITP
Aug 9, 2006·Thrombosis and Haemostasis·Massimo FranchiniRachel Stenner
Jan 4, 2007·Annals of Internal Medicine·Donald M ArnoldJohn G Kelton
May 16, 2007·Annals of Hematology·R SimanekI Pabinger
Sep 18, 2007·Annals of Hematology·Jaime Garcia-ChavezUNKNOWN Mexican Hematology Study Group
Aug 8, 2008·Blood·Theodore E Warkentin, Donald M Arnold
Apr 28, 2009·Blood·Douglas B CinesEline T Luning Prak

❮ Previous
Next ❯

Citations

Jun 29, 2011·Annals of Hematology·Souleymane BrahJean-Marc Durand
Aug 16, 2011·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Leonardo BoiocchiJulia Turbiner Geyer
Jun 16, 2011·Pediatric Blood & Cancer·Rachael F GraceEllis J Neufeld
Feb 18, 2011·American Journal of Hematology·Daan DierickxDrew Provan
Jun 11, 2014·American Journal of Hematology·Carlo ViscoFrancesco Rodeghiero
Aug 14, 2012·Health Expectations : an International Journal of Public Participation in Health Care and Health Policy·Karen K W WangDonald M Arnold
Sep 13, 2017·International Journal of Hematology·Ahmed S Al AskarAltaf Khan

Jul 19, 2020·La Revue de médecine interne·Samuel DeshayesBertrand Godeau

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.